Juvenescence-backed biotech snaps up biomanufacturing firm to enhance its synthetic biology and biopharma development capabilities.
Longevity nutrition biotech Chrysea has acquired biomanufacturing firm Rodon Biologics from Iberfar Group for an undisclosed amount. The strategic acquisition will boost Chrysea’s capabilities by integrating Rodon’s proficiency in protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics, and production.
A developer of “precision healthy-lifespan nutrition interventions” to help treat, manage or delay, the onset of chronic, age-related conditions, Chrysea is targeting the consumer preventive health and wellness products market. The company is working on science-backed ingredients and products targeting healthy lifespan improvements, and is focused on developing rare and hard-to-source ingredients through sustainable and eco-friendly methods, avoiding reliance on chemical synthesis.
Rodon specializes in developing biopharmaceuticals, including novel antibody-based multi-specific formats, cytokines, growth factors, consumer products, enzymes, and food ingredients. With more than two decades of expertise in biomanufacturing and biological product development, Rodon will continue to operate independently, serving its existing and new clients while contributing to Chrysea’s projects.
The strategic acquisition also aims to drive capital-efficiency for Chrysea, tapping into Rodon’s extensive talent pool to enhance its position in synthetic biology and biopharmaceuticals development.
“This acquisition places Chrysea at a vantage point to address the surging demand for development and biomanufacturing within the biopharmaceutical and synthetic biology sectors,” said Pedro de Noronha Pissarra, CEO of Chrysea.
The Rodon acquisition was supported by longevity biotech Juvenescence, which is an investor in Chrysea and collaborates with the company on the development of one of its products.
“This acquisition represents a truly remarkable opportunity,” said Richard Marshall, CEO of Juvenescence.
